Oppenheimer raised the firm’s price target on Revolution Medicines (RVMD) to $75 from $70 and keeps an Outperform rating on the shares. The firm notes that following the recent update describing Revolution Medicines’ confidence in owning the PDAC space, the company’s Q1 update, supported by a wealth of promising clinical results, further extends the potential dominance to NSCLC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Strategic Advancements in NSCLC Treatment Drive Buy Rating
- Revolution Medicines’ Promising RAS+ NSCLC Market Position and Drug Efficacy Justify Buy Rating
- Buy Recommendation for Revolution Medicines: Promising RAS(ON) Platform and Strong Financial Position
- Revolution Medicines Reports Q1 2025 Financial Results
- Closing Bell Movers: Arm sinks over 10% as guidance falls short